369 related articles for article (PubMed ID: 29364918)
1. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
Chamorro V; Morales-Cano D; Milara J; Barreira B; Moreno L; Callejo M; Mondejar-Parreño G; Esquivel-Ruiz S; Cortijo J; Cogolludo Á; Barberá JA; Perez-Vizcaino F
PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
3. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
4. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
Thorsen LB; Eskildsen-Helmond Y; Zibrandtsen H; Stasch JP; Simonsen U; Laursen BE
Eur J Pharmacol; 2010 Nov; 647(1-3):147-54. PubMed ID: 20828552
[TBL] [Abstract][Full Text] [Related]
5. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
Næsheim T; How OJ; Myrmel T
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299
[TBL] [Abstract][Full Text] [Related]
7. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
8. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
[TBL] [Abstract][Full Text] [Related]
9. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
10. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
11. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
[TBL] [Abstract][Full Text] [Related]
12. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study.
Milara J; Escrivá J; Ortiz JL; Juan G; Artigues E; Morcillo E; Cortijo J
Eur Respir J; 2016 Jun; 47(6):1737-49. PubMed ID: 27009174
[TBL] [Abstract][Full Text] [Related]
13. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats.
Su CL; Yuan DW; Chiang LL; Lee HL; Chen KH; Wang D
Transplant Proc; 2012 May; 44(4):929-32. PubMed ID: 22564588
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
Sandner P; Becker-Pelster EM; Stasch JP
Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs.
Weissmann N; Voswinckel R; Tadic A; Hardebusch T; Ghofrani HA; Schermuly RT; Seeger W; Grimminger F
Am J Respir Cell Mol Biol; 2000 Aug; 23(2):222-7. PubMed ID: 10919989
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.
Alencar AK; Carvalho FI; Silva AM; Martinez ST; Calasans-Maia JA; Fraga CM; Barreiro EJ; Zapata-Sudo G; Sudo RT
PLoS One; 2018; 13(4):e0195047. PubMed ID: 29677206
[TBL] [Abstract][Full Text] [Related]
17. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
Benza R; Mathai S; Nathan SD
Respir Med; 2017 Jan; 122 Suppl 1():S28-S34. PubMed ID: 27890470
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
[TBL] [Abstract][Full Text] [Related]
20. Role of pentose phosphate pathway-derived NADPH in hypoxic pulmonary vasoconstriction.
Gupte SA; Okada T; McMurtry IF; Oka M
Pulm Pharmacol Ther; 2006; 19(4):303-9. PubMed ID: 16203165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]